[Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis]
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Mengarelli C
Record ID 32014000269
Authors' objectives: To assess the available evidence on the efficacy, safety and coverage related issues on the use of Etarnercept, Adalimumab, Infliximab and Golimumab in patients with ankylosing spondylitis and reactive arthritis.
Authors' recomendations: The quality of the evidence found is high for ankylosing spondylitis and very low for reactive arthritis. Anti-TNF-alpha therapy has proved to better control ankylosing spondylitis inflammatory symptoms when compared to placebo or DMDs. The clinical practice guidelines recommend their use in patients refractory to standard therapy with active disease for over 4 weeks and a BASDAI score = or >4 (0–10). Patients with axial manifestations may start anti-TNF-alpha therapy without having previously received DMDs. In patients with peripheral arthritis, they are indicated after failure to sulfasalazine therapy. No evidence was found demonstrating anti-TNF-alpha efficacy in reactive arthritis. No evidence or recommendations were found comparing the relative effectiveness of the different anti-TNFs-alpha drugs.
Project Status: Completed
Year Published: 2013
URL for published report: https://www.iecs.org.ar/home-ets/?cod_publicacion=1522&origen_publicacion=publicaciones
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Immunosuppressive Agents
- Spondylitis, Ankylosing
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.